CODX (37) XAIR (42) AMIX (37) IVF (43) ⌘ Pro Terminal →

IceCure Medical Ltd. (ICCM) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell ICCM stock right now?

IceCure Medical Ltd. (ICCM) currently earns a Roarable Rating of D (Sell — SELL) with 46/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is ICCM's 12-month price target and RQD AI Jury consensus?

ICCM's 12-month base price target is $0.91 (range $0.71 to $24.66), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$0.96 -2.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.95

IceCure Medical Ltd. (ICCM) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $3.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.95 (-0.57%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICCM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY ICCM SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (33% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 18.1 (OVERSOLD (<32))

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (22% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.10-3.6% Next Q

Q2 (-2Q)

Grade C-$1.06-4.7% Next Q

Q3 (-1Q)

Grade D$1.01-5% Next Q

Current

Grade D$0.96-6.1% Hist 90D α

Trajectory: C- (54) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ICCM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ICCM currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.66) and Max Pain ($1.01) forces dealer call-delta covering toward $24.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICCM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ICCM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

18.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$0.96H: $23

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ICCM

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 36.3% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

15/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like ICCM

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ICCM)

✓Walkthrough of ICCM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ICCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -88.81%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.94H $0.96L $0.82C $0.96VOL 50.2K

SUP: $0.55SMA50: $1.66SMA200: $7.93

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ICCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ICCM Butterfly Map → + Track ICCM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +2.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ICCM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ICCM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ICCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICCM)

Health Care Rank #464 of 1016 ⚔️ CODX vs ICCM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ICCM vs. CODX, XAIR, AMIX, IVF)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, IceCure Medical Ltd. (ICCM) ranks #464 by composite RQD confidence (46/100, grade D) and #977 by equity capitalization ($3.3M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while ICCM leads on capital efficiency and profitability with -35.0% ROIC and 36.3% gross margin. ICCM currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ICCM ACTIVE IceCure Medical Ltd.	D	46/100	—	36.3%	-35.0%	-2.13%	$3.3M	Benchmark Subject
CODX Co-Diagnostics Inc.	D-	37/100	—	64.3%	-35.0%	-10.49%	$3.5M	/codx-vs-iccm →
XAIR Beyond Air Inc.	D-	42/100	112.1x	3.3%	-35.0%	-2.12%	$3.8M	/xair-vs-iccm →
AMIX Autonomix Medical Inc.	D-	37/100	—	—	-35.0%	-5.12%	$4.0M	/amix-vs-iccm →
IVF INVO Fertility Inc.	D-	43/100	—	96.0%	-35.0%	-3.60%	$2.5M	/ivf-vs-iccm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001584371

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IceCure Medical Ltd. (ICCM) reported GAAP revenue of $3.4M (+2.7% vs. FY2024 revenue of $3.3M , and +4.6% cumulative change since FY2023) , GAAP net income of -$15.1M, operating cash flow of -$14.6M, and free cash flow of -$14.6M (-15.6% YoY). On the balance sheet, ICCM closed FY2025 with $13.9M in total assets against $13.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.4M	-$15.1M	-$14.6M	-$14.6M	$13.9M	$13.0K
FY2024 (FY)	2024-12-31	$3.3M	-$15.3M	-$12.6M	-$12.6M	$12.6M	$161.0K
FY2023 (FY)	2023-12-31	$3.2M	-$14.7M	-$12.6M	-$12.6M	—	—

3. ICCM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ICCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, IceCure Medical Ltd. (NASDAQ: ICCM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.96 (-2.13% 1D, market cap $3.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ICCM ranks #464 in composite RQD confidence.

How does ICCM compare to CODX and XAIR in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), ICCM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 36.3%, and ROIC of -35.0%. By comparison, CODX (Co-Diagnostics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M) and XAIR (Beyond Air Inc.) posts a D- grade (42/100 RQD, P/E 112.1x, ROIC -35.0%, cap $3.8M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while ICCM leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ICCM?

Per ICCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001584371), IceCure Medical Ltd. generated $3.4M in revenue (+2.7% YoY), -$15.1M in net income, and -$14.6M in free cash flow against $13.9M in total assets and $13.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ICCM trading relative to its 50-day, 200-day, and 52-week technical levels?

ICCM last traded at $0.96 (-2.13% on volume of 56,714 shares), positioning the stock -42.17% below its 50-day simple moving average ($1.66) and -87.89% below its 200-day simple moving average ($7.93). Across its 52-week range of $0.82 to $23.49, ICCM sits at the 0.6% percentile with a 14-day RSI of 18.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.08).

ICCM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ICCM stock right now?

IceCure Medical Ltd. (ICCM) currently earns a Roarable Rating of D (Sell — SELL) with 46/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is ICCM's 12-month price target and RQD AI Jury consensus?

ICCM's 12-month base price target is $0.91 (range $0.71 to $24.66), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ICCM RQD Cockpit ICCM 12M Forecast ICCM Earnings & Move ICCM Dividends & DRIP ICCM Insiders & 13F ICCM Whale Options ICCM Profit Sankey ICCM News & Why